Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2011-01-18
2011-01-18
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C424S283100, C514S023000, C514S053000
Reexamination Certificate
active
07871631
ABSTRACT:
The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-α antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.
REFERENCES:
patent: 5656272 (1997-08-01), Le et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6790444 (2004-09-01), Le et al.
patent: 6835823 (2004-12-01), Le et al.
patent: 6991791 (2006-01-01), Le et al.
patent: 2001/0027249 (2001-10-01), Le et al.
patent: 2002/0022720 (2002-02-01), Le et al.
patent: 2002/0114805 (2002-08-01), Le et al.
patent: 2002/0141996 (2002-10-01), Le et al.
patent: 2002/0146419 (2002-10-01), Le et al.
patent: 2003/0017584 (2003-01-01), Le et al.
patent: 2003/0054004 (2003-03-01), Le et al.
patent: 2003/0064040 (2003-04-01), Lukacsko
patent: 2003/0133935 (2003-07-01), Le et al.
patent: 2003/0144484 (2003-07-01), Le et al.
patent: 2003/0147891 (2003-08-01), Le et al.
patent: 2003/0175275 (2003-09-01), Le et al.
patent: 2003/0175837 (2003-09-01), Le et al.
patent: 2003/0176676 (2003-09-01), Le et al.
patent: 2003/0180299 (2003-09-01), Le et al.
patent: 2003/0181695 (2003-09-01), Le et al.
patent: 2003/0187231 (2003-10-01), Le et al.
patent: 2003/0194402 (2003-10-01), Le et al.
patent: 2003/0198634 (2003-10-01), Le et al.
patent: 2003/0198641 (2003-10-01), Le et al.
patent: 2003/0204066 (2003-10-01), Le et al.
patent: 2004/0115200 (2004-06-01), Le et al.
patent: 2004/0138427 (2004-07-01), Le et al.
patent: 2005/0037008 (2005-02-01), Le et al.
patent: 2005/0074454 (2005-04-01), Le et al.
patent: 2006/0013816 (2006-01-01), Le et al.
patent: 2006/0018905 (2006-01-01), Le et al.
patent: 2006/0018906 (2006-01-01), Le et al.
patent: 2006/0024310 (2006-02-01), Le et al.
patent: 2006/0211631 (2006-09-01), Mitsumoto et al.
patent: 0 689 835 (1996-01-01), None
patent: 8-73351 (1996-03-01), None
patent: 8-505365 (1996-06-01), None
patent: 11-503752 (1999-03-01), None
patent: 92/16553 (1992-10-01), None
patent: 94/08619 (1994-04-01), None
Hanauer SB, et al. The Lancet 359 (9317):1541-1549, May 4, 2002.
Hitoshi Asakura, et al., “Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings”, Journal of Gastroenterology and Hepatology, 16, 2001, pp. 763-769.
M. Takazoe, et al., “Targeted therapy for Crohn's disease (CD)-monoclonal antibody anti-TNF-α therapy”, Journal of Japan Society of Coloproctology, 56, 2003, pp. 841-848 and partial English translation.
Torao Tanaka, M.D., et al., “New therapeutic strategy for inflammatory bowel diseases to improve QOL Effect of infliximab treatment for active refractory Crohn's disease”, Gastroenterology, 37(5), 2003, pp. 456-463 and partial English translation.
Present, et al., “Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease,” The New England Journal of Medicine, vol. 340, No. 18, May 6, 1999, pp. 1398-1405.
Nomura M, et al., Nippon Shokkibyo Gakkai Zasshi, 92(1), Abstract, Jan 1995.
Sanders TA, American J. Clinical Nutrition, 71(Suppl 1), Abstract, Jan 2000.
Ajinomoto Co. Inc.
Landsman Robert
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Methods of inhibiting the lowering of antihuman TNF-α... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting the lowering of antihuman TNF-α..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting the lowering of antihuman TNF-α... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651098